Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.56 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8834773 | 0.89 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL6089132 | 0.87 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL8782794 | 0.85 | CYSLTR1 (0.50) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL15065304 | 0.79 | PDE10A (0.46) | CYSLTR1CYSLTR2ALDH1A1GPBAR1PDE10A | |
| SCHEMBL30078106 | 0.79 | PDE10A (0.46) | CYSLTR1CYSLTR2ALDH1A1GPBAR1PDE10A | |
| SCHEMBL25435433 | 0.78 | GPBAR1 (0.56) | CYSLTR1CYSLTR2SMN1; SMN2GPBAR1PDE10A | |
| SCHEMBL9847314 | 0.78 | CYSLTR1 (0.58) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL8800848 | 0.77 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL9843295 | 0.77 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL1004347 | 0.77 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
| EP-0902007-B1 | CHALCONE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2003-11-05 | — | — | EP | disclosed |
| US-6046212-A | ANTIALLERGIC AGENTS | KOWA CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0902007-A1 | CHALCONE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-03-17 | — | — | EP | disclosed |
| EP-0291916-B1 | DITHIOACETAL COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-12 | — | — | EP | disclosed |
| US-5081126-A | QUINOLYL- AND ISOQUINOLYL-METHOXYPHENYL-DITHIOACETYL DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| US-4963576-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; 5-LIPOXYGENASE INHIBITOR | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
| EP-0291916-A1 | Dithioacetal compounds, processes for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | CYSLTR1 374/4885CYSLTR2 538/4885ALDH1A1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.